Needham analyst Ami Fadia downgraded Intra-Cellular (ITCI) to Hold from Buy without a price target after Johnson & Johnson said will acquire all outstanding shares of Intra-Cellular for a payment of $132.00 per share in cash.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley
- Morning Movers: Intra-Cellular surges following deal to be bought by J&J
- Johnson & Johnson to Acquire Intra-Cellular Therapies
- M&A News: Intra-Cellular Stock Rallies 36% on News of $14.6B Acquisition by Johnson & Johnson
- Johnson & Johnson to acquire Intra-Cellular for $132.00 per share in cash